Physician profile
Daniel Kohm
NPI 1649233172
$4,955.97
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,316 · 2020: $291 · 2021: $945 · 2022: $1,448 · 2023: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,641.83 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $622.36 | 2019-2023 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $595.48 | 2019-2023 | Gattex, Entyvio |
| Celgene Corporation | $329.89 | 2021-2023 | Zeposia |
| Redhill Biopharma INC. | $266.72 | 2021-2022 | |
| Gilead Sciences, INC. | $202.64 | 2019-2023 | |
| Janssen Biotech, INC. | $195.14 | 2019-2023 | Stelara, Remicade, Simponi Aria |
| Genzyme Corporation | $148.15 | 2022-2023 | |
| Qol Medical, LLC | $135.93 | 2021-2023 | Sucraid |
| Merck Sharp & Dohme LLC | $122.40 | 2019-2023 | Dificid |
| Janssen Scientific Affairs, LLC | $96.65 | 2019 | |
| Pharmacosmos Therapeutics INC. | $71.10 | 2022 | |
| Allergan, INC. | $68.34 | 2019 | |
| Vivus LLC | $64.73 | 2021-2023 | Qsymia |
| Intercept Pharmaceuticals, INC. | $59.20 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $57.66 | 2020-2023 | |
| Ferring Pharmaceuticals INC. | $47.37 | 2021-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $44.60 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $25.48 | 2023 | |
| Shire North American Group INC | $22.87 | 2019 | |
| Shionogi INC | $20.62 | 2019 | |
| Braintree Laboratories, INC. | $19.37 | 2019 | |
| Lilly USA, LLC | $17.59 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $16.90 | 2022 | |
| Csl Behring | $16.72 | 2022 | |
| Daiichi Sankyo INC. | $16.37 | 2019 | |
| Emd Serono, INC. | $13.54 | 2019 | |
| Alfasigma USA, INC. | $12.14 | 2020 | |
| Romark Laboratories, Lc | $4.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kohm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.